U.S. Markets close in 6 hrs 9 mins

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
108.17-27.13 (-20.05%)
As of 9:51AM EDT. Market open.

Cassava Sciences, Inc.

7801 North Capital of Texas Highway
Suite 260
Austin, TX 78731
United States
512 501 2444

Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Remi BarbierFounder, Chairman, Pres & CEO936.12kN/A1960
Mr. Eric J. SchoenChief Financial Officer251.93kN/A1968
Dr. Nadav FriedmannChief Medical Officer & Director345kN/A1943
Dr. George ThorntonSr. VP of TechnologyN/AN/AN/A
Mr. Michael ZamlootSr. VP of Technical OperationsN/AN/AN/A
Dr. Michael MarsmanSr. VP of Regulatory AffairsN/AN/AN/A
Dr. Lindsay H. Burns Ph.D.Sr. VP of NeuroscienceN/AN/AN/A
Dr. James W. Kupiec M.D.Chief Clinical Devel. OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Corporate Governance

Cassava Sciences, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.